Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

JCO Precis Oncol. 2022 Feb:6:e2100456. doi: 10.1200/PO.21.00456.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal, Humanized
  • Camptothecin / analogs & derivatives
  • Humans
  • Immunoconjugates
  • Indoles
  • Mutation
  • Neoplasms* / drug therapy
  • Recombinational DNA Repair
  • Starfish*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunoconjugates
  • Indoles
  • rucaparib
  • sacituzumab govitecan
  • Camptothecin